Option chain shows key data for AppSwarm's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for AppSwarm.

AppSwarm (OTC:SWRM) Stock, Option Chain

AppSwarm Inc is a software company, that focuses on accelerating the development of applications by providing funding, technology, and marketing expertise. Its primary focus is on developing software platforms and mobile apps for rapid-growth sectors such as business enterprises, e-commerce and retail, blockchain, and the gaming industry. Its products and services include Application development, Software development, E-Commerce development, Website development, and General technology development.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Penny Stocks

Markets

Movers

Trading Ideas

SWRM

Dogecoin (CRYPTO: DOGE) traded 1% lower over 24 hours at $0.298 early Friday.

What’s Moving? The Shiba Inu-themed cryptocurrency was up 8.35% over a seven-day trailing period at press time.

What&#39;s Going On With Dogecoin Today?

Tech

What’s Moving: The shares of OTC-listed company AppSwarm Inc. (OTC: SWRM) jumped 77.6% in Thursday’s trading session at $0.014.

This Little-Known OTC Stock Jumped 77% Today — Thanks To Dogecoin

TSLA

AppSwarm, Corp (OTC: SWRM) announced a global developer initiative centered around DogeLab.io’s blockchain research project related to building “a sort of decentralized network” of Dogecoin (DOGE) development teams.

Dogecoin Sees &#39;Global Developer Initiative&#39; To Help Build Commercial Apps On Top Of Its Blockchain: What You Need To Know

AppSwarm Inc

Natural Grocers&#xAE;, Colorado's trusted organic and natural grocery retailer since 1955, is gearing up for its sixth annual&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4371595-1&amp;h=1263298437&amp;u=https%3A%2F%2Fwww.naturalgrocers.com%2Fcolorado-days%3Futm_source%3Dpr%26utm_medium%3Dpress-release%26utm_campaign%3Dco-days-2025&amp;a=Celebrate+Colorado+event">Celebrate Colorado event</a>. From March 3-5, all 45 Colorado stores will offer exclusive savings, giveaways, and sweepstakes. With nearly 1,600 Natural Grocers good4u&#xAE; Crew members and its headquarters in Lakewood, Natural Grocers remains deeply rooted in the Colorado community—honoring its home state with three days of festivities, highlighting local brands and products.
 &nbsp;

NGVC

Natural Grocers Hosts Sixth Annual Celebrate Colorado Event With Deals, Giveaways, And Local Brands

ORGN

Origin Confirms Three New CapFormer Lines Nearing Completion, Eight Total Lines Expected By End Of Year

DFLI

Dragonfly Reveals Debt Restructuring With Maturity Extension And Covenant Waiver; Concurrent $3.5M Capital Raise

LENSAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNSR#NASDAQ">LNSR</a>) reported quarterly losses of $(1.61) per share which missed the analyst consensus estimate of $(0.18) by 794.44 percent. This is a 360 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $16.73 million which beat the analyst consensus estimate of $14.90 million by 12.29 percent. This is a 38.22 percent increase over sales of $12.11 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

LNSR

LENSAR Q4 EPS $(1.61) Misses $(0.18) Estimate, Sales $16.73M Beat $14.90M Estimate

Guidance

EVRG

Evergy Reaffirms 2025 GAAP and Adjusted EPS Guidance Of $3.92-$4.12 Vs. $4.04 Est.

Wells Fargo analyst Joe Quatrochi maintains Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Equal-Weight and lowers the price target from $540 to $520.

Price Target

Analyst Ratings

SNPS

Wells Fargo Maintains Equal-Weight on Synopsys, Lowers Price Target to $520

Biotech

Health Care

General

ACET

The FDA Has Granted Fast Track Designation To Adicet Bio's ADI-001 For The Potential Treatment Of Adult Patients With Systemic Sclerosis

<ul>
<li>Ironwood 2025 Financial Guidance. Ironwood continues to expect:</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
2025 Guidance
(February 2025)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">U.S. LINZESS Net Sales</td>
<td colspan="1" rowspan="1">
$800 - $850 million
High single digit prescription demand growth, more than offset by expected price erosion due to Medicare Part D redesign
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue1</td>
<td colspan="1" rowspan="1">$260 - $290 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA2</td>
<td colspan="1" rowspan="1">&gt;$85 million</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">1 Ironwood's U.S. collaborative arrangements revenue includes reimbursement from AbbVie for a portion of Ironwood's commercial expenses related to sales of LINZESS in the U.S. The FY2025 total revenue guidance accounts for the impact of the reduction to Ironwood's commercial expenses and corresponding reimbursement from AbbVie due to Ironwood's strategic reorganization.</td>
</tr>
</tbody>
</table>
</figure>

IRWD

Ironwood Pharmaceuticals 2025 Outlook: Expects Revenue Of $260M–$290M Vs. $287.583M Est., Sees Adjusted EBITDA Above $85M

TGLS

Tecnoglass Introducing FY025 Outlook For Revenues Of $940M - $1.02B (Est $979.975M), Representing Growth Of 10% At Midpoint Of Range

Wells Fargo analyst Ken Gawrelski maintains eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) with a Equal-Weight and raises the price target from $61 to $64.

EBAY

Wells Fargo Maintains Equal-Weight on eBay, Raises Price Target to $64

Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.46 by 2.17 percent. This is a 16.07 percent decrease over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $273.68 million which beat the analyst consensus estimate of $223.10 million by 22.67 percent. This is a 14.66 percent increase over sales of $238.69 million the same period last year.

Macerich Q4 FFO $0.47 Beats $0.46 Estimate, Sales $273.68M Beat $223.10M Estimate

Vistra Reaffirmed Guidance For 2025 Ongoing Operations Adjusted EBITDA Of $5.5B To $6.1B

Key Preclinical Findings on AEX-2 (20 mg/kg, IP)
Recent preclinical advancements have demonstrated the multi-target potential of DOXA compounds, including AEX-41 and AEX-2, in redefining sleep-wake regulation and neuroprotection. In orexin-deficient mouse models, these compounds exhibited strong wake-promoting effects and sleep-wake cycle stabilization, reinforcing their potential as next-generation therapeutics. Key findings include:
<ul>
<li>Wakefulness Enhancement: AEX-2 significantly increased total wake duration while maintaining a stable wake architecture, avoiding excessive fragmentation.</li>
<li>REM Sleep Preservation: Unlike traditional stimulants, AEX-2 regulated rapid eye movement ("REM") sleep dynamics, minimizing undesired suppression and sleep rebound effects.</li>
<li>Reduction in Cataplexy: AEX-2 effectively reduced the frequency and duration of cataplexy episodes, a crucial advancement for treating narcolepsy type 1 (NT1).</li>
</ul>
These data underscore the potential of AEX-2 as a safer and more targeted alternative to existing orexin-based therapies, such as TAK-994 and TAK-861, which have been hindered by safety concerns.
Expanding the AEX Platform: AEX-2 and AEX-41 in Neurodegeneration and Metabolic Disorders
Beyond narcolepsy, NLS Pharmaceutics and Aexon Labs are advancing AEX-2 and AEX-41 into new therapeutic areas, leveraging their multi-target mechanisms that extend to neuroinflammatory and metabolic pathways.
<ul>
<li>Targeting&nbsp;Neuroinflammation: Recent discoveries highlight AEX compounds' engagement with the Sigma-1 receptor, which plays a key role in neuroprotection, synaptic plasticity, and REM sleep regulation.</li>
<li>Potential in ALS and Neurodegenerative Diseases: Sigma-1 receptor modulation, combined with orexin receptor activation, suggests AEX-41 may have applications in ALS and Parkinson's disease, particularly in preserving motor function and reducing neuroinflammation.</li>
<li>Addressing Diabetes-Associated Neurological Disorders ("DANS"): Given the link between orexin signalling, metabolic regulation, and sleep disorders, the multi-target properties of DOXA compounds such as AEX-2 and AEX-41 could provide new therapeutic avenues for diabetes-related neuropathy and cognitive decline.</li>
</ul>
Aexon Labs, known for its cutting-edge computational chemistry and AI-driven drug discovery, has played a key role in optimizing these multi-target molecules, ensuring high blood-brain barrier penetration and selective receptor affinity

NLSP

NLS Pharmaceutics In Collaboration With Aexon Labs Announced New Preclinical Findings On Aex-2 For Narcolepsy And Related Neurological Disorders

Palmer Square Capital BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSBD#NYSE">PSBD</a>) reported quarterly earnings of $0.45 per share which met the analyst consensus estimate. This is a 22.41 percent decrease over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $34.87 million which beat the analyst consensus estimate of $34.86 million by 0.04 percent. This is a 16.93 percent increase over sales of $29.82 million the same period last year.

PSBD

Palmer Square Capital BDC Q4 GAAP EPS $0.45, Inline, Sales $34.87M Beat $34.86M Estimate

Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.34) by 2.94 percent. This is a 9.37 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $4.12 million which missed the analyst consensus estimate of $7.77 million by 46.99 percent. This is a 24.19 percent decrease over sales of $5.43 million the same period last year.

TNGX

Tango Therapeutics Q4 2024 GAAP EPS $(0.35) Misses $(0.34) Estimate, Sales $4.12M Miss $7.77M Estimate

Scholar Rock Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.60) by 1.67 percent. This is a 22 percent decrease over losses of $(0.50) per share from the same period last year.

SRRK

Scholar Rock Holding Q4 EPS $(0.61) Misses $(0.60) Estimate

WIIM

Freeport-McMoRan shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $40 to $48.

PureCycle Technologies Restricted & Unrestricted Cash Stood At $41.5M As Of Dec 31, 2025

Hayward Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) sees FY2025 sales of $1.060 billion-$1.100 billion vs $1.08 billion analyst estimate.

HAYW

Hayward Holdings Sees FY2025 Sales $1.060B-$1.100B vs $1.08B Est

Business Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">First Quarter 2025 Guidance</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Full-Year 2025 Guidance</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$130 – 133 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$555 – 570 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Year-over-year revenue growth (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">29</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">17</td>
<td colspan="1" rowspan="1">%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$28 – 30 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$132 – 138 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA margin (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">22</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">24</td>
<td colspan="1" rowspan="1">%</td>
</tr>
</tbody>
</table>
</figure>

Comments

AppSwarm

AppSwarm (SWRM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga